|04/05/17||Xtant™ Medical Receives Going Concern Opinion|
|BELGRADE, Mont., April 05, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2016, which was filed on March 29, 2017 with the Securities and Exchange Commission, its audited financial statements contained a going concern qualification paragraph in the audit opinion from its indepen... |
|03/09/17||Xtant™ Medical Reports Record Fourth Quarter Revenue of $24.5 million, 10% Growth Compared to Prior Year Period|
|See footnote about the use of pro forma financial information
Fourth Quarter 2016 Highlights:
Consolidated total revenue increased 9.9% to a record $24.5 million compared to fourth quarter 2015 revenue of $22.3 million
Consolidated gross profit increased 17.4% to $17.5 million compared to fourth quarter 2015 gross profit of $14.9 million
Consolidated gross margins improved to 71.6%, compared to 67.0% reported in the fourth quarter of 2015
Full-Year 2016 Highlights:
|03/01/17||Xtant Medical to announce Fourth Quarter and Full Year 2016 Results on March 9th, 2017|
|BELGRADE, Mont., March 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2016, after the close of the financial markets on Thursday, March 9, 2017.
An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and John Gandolfo, Ch... |
|02/22/17||Xtant Medical Announces Appointment of Carl O'Connell to Permanent CEO|
|BELGRADE, Mont., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O’Connell as the permanent CEO, effective February 17th, 2017. Mr. O'Connell previously served as president of Xtant since October of 2016 and was appointed as interim CEO on January 21st, 2017.
Prior to joining Xtant Medical, Mr. O'Connell most recently served as the Vice P... |